JP6186427B2 - 抗菌性ファージのカクテルを含む組成物及び細菌感染症を処置するためのその使用 - Google Patents

抗菌性ファージのカクテルを含む組成物及び細菌感染症を処置するためのその使用 Download PDF

Info

Publication number
JP6186427B2
JP6186427B2 JP2015501614A JP2015501614A JP6186427B2 JP 6186427 B2 JP6186427 B2 JP 6186427B2 JP 2015501614 A JP2015501614 A JP 2015501614A JP 2015501614 A JP2015501614 A JP 2015501614A JP 6186427 B2 JP6186427 B2 JP 6186427B2
Authority
JP
Japan
Prior art keywords
bacteriophage
treatment
pharmaceutical composition
seq
phage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015501614A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015512384A5 (enExample
JP2015512384A (ja
Inventor
メンデス ジョアン ジョアン ドゥアルテ アウベス
メンデス ジョアン ジョアン ドゥアルテ アウベス
レアンドロ クララ イザベル ロドリゲス
レアンドロ クララ イザベル ロドリゲス
コルテ−レアル ソフィア フォルカー
コルテ−レアル ソフィア フォルカー
Original Assignee
テクニファー−インダストリア テクニカ ファーマシューティカ，エス．エー．
テクニファー−インダストリア テクニカ ファーマシューティカ，エス．エー．
テクノファージ， インベスティガサン エ デセンボルビメント エム ビオテクノロジア，エスエー
テクノファージ， インベスティガサン エ デセンボルビメント エム ビオテクノロジア，エスエー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by テクニファー−インダストリア テクニカ ファーマシューティカ，エス．エー．, テクニファー−インダストリア テクニカ ファーマシューティカ，エス．エー．, テクノファージ， インベスティガサン エ デセンボルビメント エム ビオテクノロジア，エスエー, テクノファージ， インベスティガサン エ デセンボルビメント エム ビオテクノロジア，エスエー filed Critical テクニファー−インダストリア テクニカ ファーマシューティカ，エス．エー．
Publication of JP2015512384A publication Critical patent/JP2015512384A/ja
Publication of JP2015512384A5 publication Critical patent/JP2015512384A5/ja
Application granted granted Critical
Publication of JP6186427B2 publication Critical patent/JP6186427B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/32—Surgical cutting instruments
    • A61B17/3205—Excision instruments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/32—Surgical cutting instruments
    • A61B2017/320004—Surgical cutting instruments abrasive
    • A61B2017/320008—Scrapers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
JP2015501614A 2012-03-19 2013-03-19 抗菌性ファージのカクテルを含む組成物及び細菌感染症を処置するためのその使用 Active JP6186427B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261612531P 2012-03-19 2012-03-19
US61/612,531 2012-03-19
PCT/PT2013/000016 WO2013141730A1 (en) 2012-03-19 2013-03-19 Compositions comprising cocktails of antibacterial phages and uses thereof for the treatment of bacterial infections

Publications (3)

Publication Number Publication Date
JP2015512384A JP2015512384A (ja) 2015-04-27
JP2015512384A5 JP2015512384A5 (enExample) 2016-05-19
JP6186427B2 true JP6186427B2 (ja) 2017-08-23

Family

ID=48534472

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015501614A Active JP6186427B2 (ja) 2012-03-19 2013-03-19 抗菌性ファージのカクテルを含む組成物及び細菌感染症を処置するためのその使用

Country Status (13)

Country Link
US (1) US9962419B2 (enExample)
EP (1) EP2833899B1 (enExample)
JP (1) JP6186427B2 (enExample)
CN (1) CN104519893B (enExample)
AU (1) AU2013235883B2 (enExample)
BR (1) BR112014023321B1 (enExample)
CA (1) CA2867418C (enExample)
DK (1) DK2833899T3 (enExample)
ES (1) ES2814024T3 (enExample)
PT (1) PT2833899T (enExample)
RU (1) RU2654596C2 (enExample)
SG (1) SG11201405829WA (enExample)
WO (1) WO2013141730A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2865383A1 (en) * 2013-10-25 2015-04-29 Pherecydes Pharma Phage therapy of pseudomonas infections
WO2016066722A2 (en) * 2014-10-28 2016-05-06 Ian Humphery-Smith Bacteriophage combinations for human or animal therapy
US10455983B2 (en) 2015-09-10 2019-10-29 Prince Castle LLC Modular food holding system
US20170157186A1 (en) * 2015-12-02 2017-06-08 Smart Phage, Inc. Phage to treat bacteria on skin
US11554158B2 (en) 2016-04-13 2023-01-17 Northeast Ohio Medical University GPNMB compositions for treatment of skin wounds
US11672839B2 (en) 2016-12-05 2023-06-13 Technechnophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Bacteriophage compositions comprising respiratory antibacterial phages and methods of use thereof
WO2018146437A1 (en) 2017-02-13 2018-08-16 Biocontrol Limited Therapeutic bacteriophage compositions
WO2019050902A1 (en) * 2017-09-05 2019-03-14 Adaptive Phage Therapeutics, Inc. METHODS OF DETERMINING THE SENSITIVITY PROFILE OF A BACTERIAL STRAIN TO A THERAPEUTIC COMPOSITION
IL274002B2 (en) * 2017-10-19 2026-03-01 Mona E Buice A topical preparation for improved healing of open wounds
JP7247192B2 (ja) * 2017-12-11 2023-03-28 アダプティブ ファージ セラピューティクス， インコーポレイテッド ファージ分注システム
US11654166B2 (en) 2018-01-02 2023-05-23 Armata Pharmaceuticals, Inc. Therapeutic bacteriophage compositions for treating Staphylococcus infection
CN109082414B (zh) * 2018-06-29 2020-11-13 浙江工业大学 一种金黄色葡萄球菌噬菌体及应用
US11155606B2 (en) 2018-07-24 2021-10-26 Medimmune, Llc Antibody directed against S. aureus clumping factor a (ClfA)
CN109730235A (zh) * 2019-02-01 2019-05-10 珠海横琴普罗恩能医用食品有限公司 一种用于医用食品的防腐剂
WO2020237044A1 (en) * 2019-05-21 2020-11-26 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Bacteriophages for the treatment of tuberculosis
WO2021222257A1 (en) 2020-04-27 2021-11-04 Armata Pharmaceuticals, Inc. Bacteriophage compositions for treating pseudomonas infection
CN111643724B (zh) * 2020-07-01 2022-01-28 南京大学 一种载有噬菌体和酸性成纤维细胞生长因子的水凝胶伤口敷料的制备方法及其应用
WO2022013314A1 (en) 2020-07-14 2022-01-20 Biontech R&D (Austria) Gmbh Bacteriophage cocktails and uses thereof
WO2022013318A1 (en) 2020-07-14 2022-01-20 Biontech R&D (Austria) Gmbh New mosaic bacteriophages and uses thereof
CN112251439B (zh) * 2020-10-26 2022-06-21 齐鲁师范学院 拟南芥高温诱导启动子pHTG1及其重组载体
CN112301001B (zh) * 2020-11-03 2022-10-14 华中农业大学 金黄色葡萄球菌噬菌体lsa2311及其应用
CN113201458B (zh) * 2020-12-21 2022-05-27 青岛诺安百特生物技术有限公司 一种提高噬菌体制剂稳定性的组合物及其应用
US20240415904A1 (en) * 2021-05-12 2024-12-19 Biomx Ltd. Staphylococcus bacteriophage and uses thereof
US20240277791A1 (en) * 2021-06-11 2024-08-22 Integrated Pharma Services, Llc Device and methods for acne therapeutics: antibacterial bacteriophages and engineered lysins
DE202022102100U1 (de) 2022-04-20 2022-04-27 Prabhakar Ramesh Bhandari Synergistische antibiotische pharmazeutische Zusammensetzung zur Behandlung von Staphylococcus aureus-Infektionen
EP4626449A1 (en) * 2022-11-28 2025-10-08 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Acinetobacter baumannii phages
WO2025104708A1 (en) 2023-11-16 2025-05-22 Technophage, Investigação E Desenvolvimento Em Biotecnologia, S.A. Method for determining the susceptibility of bacteria to bacteriophages

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09511397A (ja) 1994-04-05 1997-11-18 エクスポネンシャル バイオセラピーズ，インコーポレイテッド 遺伝子型改変バクテリオファージによる抗菌治療
US5863560A (en) 1996-09-11 1999-01-26 Virotex Corporation Compositions and methods for topical application of therapeutic agents
US6138401A (en) 1999-06-25 2000-10-31 Duncan; Franklin R. Fish hook remover
CN1643139A (zh) 2002-03-25 2005-07-20 沃里克大学 抗菌剂
US20050095222A1 (en) 2003-10-29 2005-05-05 Taro Suzuki Allergen inhibitor, allergen-inhibiting method, allergen-inhibiting fiber and allergen-inhibiting sheet
US8309077B2 (en) 2004-11-02 2012-11-13 Chr. Hansen A/S Stabilized bacteriophage formulations
MX2007005279A (es) 2004-11-02 2008-03-11 Gangagen Life Sciences Inc Composiciones de bacteriofagos.
WO2006063176A2 (en) 2004-12-06 2006-06-15 The Government Of The Usa As Representedtd By The Secretary Of The Dept Of Health And Human Services Inhibition of biofilm formation using bacteriophage
CA2609357A1 (en) 2005-05-26 2006-11-30 Gangagen Life Sciences Inc. Bacterial management in animal holding systems
EP3115054B1 (en) 2009-02-06 2019-11-20 Technophage, Investigação E Desenvolvimento Em Biotecnologia, SA Antibacterial phage, phage peptides and methods of use thereof
PT104837A (pt) 2009-11-24 2011-05-24 Technophage Investiga O E Desenvolvimento Em Biotecnologia S A P?ptidos de fagos enteroc?cicos e m?todos para a sua utiliza??o
EP3443970B1 (en) * 2010-09-17 2020-09-09 Tecnifar-Indústria Técnica Farmacêutica, S.A. Antibacterial phage, phage peptides and methods of use thereof

Also Published As

Publication number Publication date
PT2833899T (pt) 2020-09-15
BR112014023321A2 (pt) 2022-02-01
JP2015512384A (ja) 2015-04-27
HK1207002A1 (en) 2016-01-22
CA2867418C (en) 2020-03-10
CN104519893A (zh) 2015-04-15
AU2013235883A1 (en) 2014-10-02
US20150150919A1 (en) 2015-06-04
SG11201405829WA (en) 2014-10-30
US9962419B2 (en) 2018-05-08
EP2833899B1 (en) 2020-06-24
AU2013235883B2 (en) 2018-01-04
BR112014023321B1 (pt) 2022-06-14
WO2013141730A1 (en) 2013-09-26
ES2814024T3 (es) 2021-03-25
EP2833899A1 (en) 2015-02-11
RU2014141941A (ru) 2016-05-20
DK2833899T3 (da) 2020-09-28
CA2867418A1 (en) 2013-09-26
RU2654596C2 (ru) 2018-05-21
CN104519893B (zh) 2020-02-07

Similar Documents

Publication Publication Date Title
RU2654596C2 (ru) Композиции коктейля, содержащие антибактериальные фаги, и способы их применения
Wei et al. Chronic wound biofilms: diagnosis and therapeutic strategies
Church et al. Burn wound infections
Bowler et al. Wound microbiology and associated approaches to wound management
Sibbald et al. Preparing the wound bed 2003: focus on infection and inflammation
Warriner et al. Infection and the chronic wound: a focus on silver
Aswathanarayan et al. Biofilm-associated infections in chronic wounds and their management
JP2018083830A (ja) 細菌性バイオフィルムを除去するためのセアプローゼの使用
JP2016519667A (ja) 創傷治癒のための組成物および使用方法
Dijksteel et al. Potential factors contributing to the poor antimicrobial efficacy of SAAP-148 in a rat wound infection model
KR20120034626A (ko) 플루오로-퀴놀론을 사용하여 폐의 세균성 감염을 치료하는 방법
US10285938B2 (en) Composition for the treatment of burns, diabetic wounds, other types of wounds and subsequently greatly reduced scarring
CN110124012B (zh) 一种颗粒溶素作为多粘菌素类抗生素增效剂的应用
US9925235B2 (en) Tilapia piscidins for use in enhancement of wound healing
HK1207002B (en) Compositions comprising cocktails of antibacterial phages and uses thereof for the treatment of bacterial infections
CN1911442B (zh) 一种用于防治创面感染的溶葡萄球菌酶冻干粉剂
US20240156860A1 (en) Method of treating infected and noninfected burn wounds
Gajakosh Prophylactic Antibiotic and Post Operative Surgical Wound Infection
Li et al. Antimicrobial effects of compound Huangbai liquid on staphylococcus aureus, Escherichia coli and MRSA: clinical, bacterial, and animal experimental studies
Yusman Comparison Between the Effect of Bioceramic and Physiological Saline Moist Gauze on the Amount of Bacterial Colony in Post-Debridement Wound Dressings of Grade 3A Open Fractures of the Leg in Hasan Sadikin Hospital, Bandung
Wahyuddin et al. Ambroxol Therapy as an Antibiofilm Candidate in Diabetic Ulcer Patients
Bazikov et al. Results of exposure of endogenous antimicrobial peptides to ESKAPE-pathogens in experiment
Mohammed Hussein et al. Role of Garlic Gel in Modulating Inflammation and Promoting Healing of Staphylococcus Aureus–Infected Oral Wounds in Albino Rats (An In-Vivo Study)
Johnson Immune Modulatory and Antimicrobial Properties of Mesenchymal Stromal Cells Delivered Systemically
JP2024108161A (ja) 皮膚疾患の処置のためのペプチド

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160322

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160322

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170330

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170614

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170629

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170731

R150 Certificate of patent or registration of utility model

Ref document number: 6186427

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R371 Transfer withdrawn

Free format text: JAPANESE INTERMEDIATE CODE: R371

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250